Gene therapy for macular degeneration: is it safe years later?
NCT ID NCT01678872
First seen Jan 18, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This study follows 18 people who already received RetinoStat, an experimental gene therapy for wet age-related macular degeneration. The goal is to see if the treatment is safe over the long term by tracking side effects and vision changes. No new participants are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Hopkins University Hospital
Baltimore, Maryland, 21287-9277, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52245, United States
Conditions
Explore the condition pages connected to this study.